• Preliminary results from any randomised, controlled COVID-19 vaccine booster trial indicate that the relative efficacy of the vaccine against the disease was 95.6% during the period when Delta was the circulating strain
• COVID-19 booster was found to have a good safety profile in trials of more than 10,000 participants aged 16 and older
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more